PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.

The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen’s website. A replay of the event will be archived for one year.

About PepGenPepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Investor ContactLaurence WattsGilmartin Group[email protected]  

Media ContactSarah SuttonArgot Partners[email protected]

You May Also Be Interested In

• Solana Unchained Emerges as a Closely Watched Solana Presale Following Product Ecosystem Reveal
• Top Meme Coin To Buy: Pipedog Selling Persists Despite 3,294% APY as AlphaPepe Stage 20 Keeps Filling
• World's First Autonomous Humanoid Tennis Match: GALBOT Robots Complete 100+ Consecutive Rallies